Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 19/20 | 0.88 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.88 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.88 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.88 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.88 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.88 |
| ▸ | MTOR | P42345 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434918 | 1.00 | PIK3CB (0.88) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| Zstk-474 SCHEMBL373282 | 0.94 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| Zstk-474 SCHEMBL29357859 | 0.94 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL26439566 | 0.92 | PIK3CB (0.74) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL373356 | 0.89 | PIK3CB (0.90) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL14702199 | 0.88 | PIK3CB (0.88) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL373357 | 0.87 | PIK3CB (0.86) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL14687684 | 0.87 | PIK3CB (0.86) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL477314 | 0.87 | PIK3CB (1.00) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL2947540 | 0.86 | PIK3CB (0.84) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129089-A1 | PREPARATION OF A 1,3,5-TRIAZINYL BENZIMIDAZOLE | MEI PHARMA, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230129089-A1 | PREPARATION OF A 1,3,5-TRIAZINYL BENZIMIDAZOLE | MEI PHARMA, INC. | 2023-04-27 | — | — | US | disclosed |
| CN-115697345-A | Preparation of 1,3, 5-triazinylbenzimidazoles | 梅制药公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115636824-A | Oxazinane compound, preparation method, pharmaceutical composition and application | 天津医科大学 | 2023-01-24 | — | — | CN | disclosed |
| CN-109810100-B | Benzofuran-containing PARP-1 and PI3K dual-target inhibitors | 中国药科大学 | 2022-03-11 | — | — | CN | disclosed |
| EP-3072890-B1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | MEI PHARMA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9611258-B2 | Dual MEK/PI3K inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611258-B2 | Dual MEK/PI3K inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-04-04 | — | — | US | disclosed |
| EP-3072890-A1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | MEI Pharma, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2604601-B1 | HETERO RING COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-7750001-B2 | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2010-07-06 | — | — | US | disclosed |
| WO-2009120094-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-10-01 | — | — | WO | disclosed |
| US-20080113987-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKIKAISHA (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1864665-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-12-12 | — | — | EP | disclosed |
| US-7307077-B2 | Heterocyclic compound and antitumor agent containing the same as effective ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-12-11 | — | — | US | disclosed |
| EP-1389617-B1 | HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KK (JP) | 2007-01-03 | — | — | EP | disclosed |
| US-20060247232-A1 | Heterocyclic compound and antitumor agent containing the same as effective ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-11-02 | — | — | US | disclosed |
| US-7071189-B2 | Heterocyclic compound and antitumor agent containing the same as active ingredient | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2006-07-04 | — | — | US | disclosed |
| US-20040116421-A1 | Heterocyclic compound and antitumor agent containing the same as active ingredient | OHARA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1389617-A1 | HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2004-02-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129089-A1 | PREPARATION OF A 1,3,5-TRIAZINYL BENZIMIDAZOLE | CYP2E1, CYP3A4, PAICS | PIK3CB 791/4885PIK3CD 1550/4885PIK3CA 1541/4885 |
| US-20080113987-A1 | IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT | IL2, NFATC1, CD47 | PIK3CB 2354/4885PIK3CD 1584/4885PIK3CA 2655/4885 |
| US-20060247232-A1 | Heterocyclic compound and antitumor agent containing the same as effective ingredient | CBR3, HCCS, CBR1 | PIK3CB 3376/4885PIK3CD 3539/4885PIK3CA 2412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.